Allergy Therapeutics (AGY) - Total Liabilities
Based on the latest financial reports, Allergy Therapeutics (AGY) has total liabilities worth GBX95.74 Million GBX (≈ $11.65K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Allergy Therapeutics - Total Liabilities Trend (2002–2025)
This chart illustrates how Allergy Therapeutics's total liabilities have evolved over time, based on quarterly financial data. See AGY working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Allergy Therapeutics Competitors by Total Liabilities
The table below lists competitors of Allergy Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CF Energy Corp
V:CFY
|
Canada | CA$849.83 Million |
|
Combigene AB
ST:COMBI
|
Sweden | Skr4.30 Million |
|
X2M Connect Ltd
AU:X2M
|
Australia | AU$9.26 Million |
|
Tatton Asset Management plc
LSE:TAM
|
UK | GBX10.97 Million |
|
ROKMASTER Resources Corp
V:RKR
|
Canada | CA$3.45 Million |
|
Strike Resources Ltd
AU:SRK
|
Australia | AU$812.49K |
|
Custodian REIT PLC
LSE:CREI
|
UK | GBX191.19 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Allergy Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AGY company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allergy Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allergy Therapeutics (2002–2025)
The table below shows the annual total liabilities of Allergy Therapeutics from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | GBX95.74 Million ≈ $11.65K |
+56.64% |
| 2024-06-30 | GBX61.12 Million ≈ $7.44K |
-5.54% |
| 2023-06-30 | GBX64.70 Million ≈ $7.87K |
+83.90% |
| 2022-06-30 | GBX35.18 Million ≈ $4.28K |
-11.05% |
| 2021-06-30 | GBX39.55 Million ≈ $4.81K |
-6.80% |
| 2020-06-30 | GBX42.44 Million ≈ $5.16K |
+37.18% |
| 2019-06-30 | GBX30.94 Million ≈ $3.76K |
+10.57% |
| 2018-06-30 | GBX27.98 Million ≈ $3.40K |
+2.81% |
| 2017-06-30 | GBX27.22 Million ≈ $3.31K |
+3.27% |
| 2016-06-30 | GBX26.36 Million ≈ $3.21K |
+62.38% |
| 2015-06-30 | GBX16.23 Million ≈ $1.97K |
+21.82% |
| 2014-06-30 | GBX13.32 Million ≈ $1.62K |
-6.79% |
| 2013-06-30 | GBX14.29 Million ≈ $1.74K |
+8.59% |
| 2012-06-30 | GBX13.16 Million ≈ $1.60K |
-53.79% |
| 2011-06-30 | GBX28.48 Million ≈ $3.47K |
+12.89% |
| 2010-06-30 | GBX25.23 Million ≈ $3.07K |
-44.25% |
| 2009-06-30 | GBX45.25 Million ≈ $5.51K |
+31.27% |
| 2008-06-30 | GBX34.47 Million ≈ $4.19K |
+123.88% |
| 2007-06-30 | GBX15.40 Million ≈ $1.87K |
+197.37% |
| 2006-06-30 | GBX5.18 Million ≈ $630.01 |
-21.26% |
| 2005-06-30 | GBX6.58 Million ≈ $800.11 |
+58.15% |
| 2004-06-30 | GBX4.16 Million ≈ $505.91 |
-25.78% |
| 2003-06-30 | GBX5.60 Million ≈ $681.60 |
-60.20% |
| 2002-06-30 | GBX14.07 Million ≈ $1.71K |
-- |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more